Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: Implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues

Molecular Pharmacology

Volumn 61, Issue 5, 2002, Pages 1033-1040

  Dunkerley, Heather A ^a   Tilley, Douglas G ^a   Palmer, Daniel ^a   Liu, Hanguan ^a   Jimmo, Sandra L ^a   Maurice, Donald H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE 3A; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; AORTA; CARDIOVASCULAR SYSTEM; CELLS, CULTURED; CYCLIC AMP; CYCLIC GMP; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; MALE; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; RNA, MESSENGER; VASOCONSTRICTION;

EID: 0036233442     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.61.5.1033     Document Type: Article

References (42)

1. Cyclic GMP-dependent protein kinase expression in coronary arterial smooth muscle in response to balloon catheter injury
2. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model
3. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype
4. Cyclic GMP phosphodiesterase-5: Target of sildenafil
5. A simple direct assay of 3′,5′-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-bononate affinity gel chromatography
6. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)
7. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis
8. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney
9. Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting
10. Cyclic nucleotides and phosphodiesterases in platelets
11. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions
12. Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model
13. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1)
14. Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: Differential regulation in cobblestone and spindle phenotypes
15. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors
16. Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation
17. Evidence from a novel human cell clone that adult vascular smooth muscle cells can convert reversibly between noncontractile and contractile phenotypes
18. Expression of cyclic GMP-inhibited phosphodiesterases 3a and 3b (pde3a and pde3b) in rat tissues: Differential subcellular localization and regulated expression by cyclic AMP
19. Phosphorylation-mediated activation and translocation of the cyclic amp- specific phosphodiesterase pDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of pde4d activity and targeting
20. Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells
21. Guanylyl cyclases and signaling by cyclic GMP
22. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle
23. Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle
24. Cell layer-specific expression of cyclic nucleotide phosphodiesterases in rat arteries: Molecular cloning using isolated cell layers from paraformaldehyde-fixed tissues
25. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: Shifting the focus from inotropy to cyclic adenosine monophosphate
26. Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction
27. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: Role of protein kinase A in vascular smooth muscle cell mitogenesis
28. Molecular control of vascular smooth muscle cell differentiation
29. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors
30. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: Implications for phosphodiesterase 3 inhibition in human cardiovascular tissues
31. Effects of cilostazol on angiographic restenosis after coronary stent placement
32. Cyclic nucleotide phosphodiesterases and vascular smooth muscle
33. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity
34. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation
35. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic proliferative phenotype
36. Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A
37. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
38. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors
39. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine
40. Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury
41. Vascular smooth muscle cell phenotypic modulation in culture is associated with reorganisation of contractile and cytoskeletal proteins
42. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B